Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2045-2322

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity ; volume:10 ; number:1 ; day:2 ; month:7 ; year:2020 ; pages:1-5 ; date:12.2020
Scientific reports ; 10, Heft 1 (2.7.2020), 1-5, 12.2020

Creator: Ayrignac, Xavier
Bars, Emmanuelle Le
Duflos, Claire
Hirtz, Christophe
Maleska Maceski, Aleksandra
Carra-Dallière, Clarisse
Charif, Mahmoud
Pinna, Frédéric
Prin, Pauline
Menjot de Champfleur, Nicolas
Deverdun, Jérémy
Kober, Tobias
Marechal, Bénédicte
Fartaria, Mario Joao
Corredor Jerez, Ricardo
Labauge, Pierre
Lehmann, Sylvain

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41598-020-67934-2

URN: urn:nbn:de:101:1-2020082820253797929394

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:01 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Ayrignac, Xavier
Bars, Emmanuelle Le
Duflos, Claire
Hirtz, Christophe
Maleska Maceski, Aleksandra
Carra-Dallière, Clarisse
Charif, Mahmoud
Pinna, Frédéric
Prin, Pauline
Menjot de Champfleur, Nicolas
Deverdun, Jérémy
Kober, Tobias
Marechal, Bénédicte
Fartaria, Mario Joao
Corredor Jerez, Ricardo
Labauge, Pierre
Lehmann, Sylvain
SpringerLink (Online service)

Other Objects (12)

Serum GFAP as a biomarker for disease severity in multiple sclerosis

Author Correction: Serum GFAP as a biomarker for disease severity in multiple sclerosis

GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA)

Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker?

Mapping of Disease Severity in Patients with Systemic Sclerosis

Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity

Refining the concept of GFAP toxicity in Alexander disease

Predicting disease severity in multiple sclerosis using multimodal data and machine learning

Genetics of disease severity in multiple sclerosis, Alzheimer’s disease, and Huntington’s disease: rejuvenating genome-wide association studies

Disease severity classification using passively collected smartphone-based keystroke dynamics within multiple sclerosis

Gut microbial factors predict disease severity in a mouse model of multiple sclerosis

Correlation of trans fatty acids with the severity of coronary artery disease lesions

Serum GFAP as a biomarker for disease severity in multiple sclerosis

Author Correction: Serum GFAP as a biomarker for disease severity in multiple sclerosis

GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA)

Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker?

Mapping of Disease Severity in Patients with Systemic Sclerosis

Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity

Refining the concept of GFAP toxicity in Alexander disease

Predicting disease severity in multiple sclerosis using multimodal data and machine learning

Genetics of disease severity in multiple sclerosis, Alzheimer’s disease, and Huntington’s disease: rejuvenating genome-wide association studies

Disease severity classification using passively collected smartphone-based keystroke dynamics within multiple sclerosis

Gut microbial factors predict disease severity in a mouse model of multiple sclerosis

Correlation of trans fatty acids with the severity of coronary artery disease lesions

Serum GFAP as a biomarker for disease severity in multiple sclerosis

Author Correction: Serum GFAP as a biomarker for disease severity in multiple sclerosis

GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA)

Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker?

Mapping of Disease Severity in Patients with Systemic Sclerosis

Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity

Refining the concept of GFAP toxicity in Alexander disease

Predicting disease severity in multiple sclerosis using multimodal data and machine learning

Genetics of disease severity in multiple sclerosis, Alzheimer’s disease, and Huntington’s disease: rejuvenating genome-wide association studies

Disease severity classification using passively collected smartphone-based keystroke dynamics within multiple sclerosis

Gut microbial factors predict disease severity in a mouse model of multiple sclerosis

Correlation of trans fatty acids with the severity of coronary artery disease lesions

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Serum GFAP as a biomarker for disease severity in multiple sclerosis

Author Correction: Serum GFAP as a biomarker for disease severity in multiple sclerosis

GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA)

Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker?

Mapping of Disease Severity in Patients with Systemic Sclerosis

Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity

Refining the concept of GFAP toxicity in Alexander disease

Predicting disease severity in multiple sclerosis using multimodal data and machine learning

Genetics of disease severity in multiple sclerosis, Alzheimer’s disease, and Huntington’s disease: rejuvenating genome-wide association studies

Disease severity classification using passively collected smartphone-based keystroke dynamics within multiple sclerosis

Gut microbial factors predict disease severity in a mouse model of multiple sclerosis

Correlation of trans fatty acids with the severity of coronary artery disease lesions

Serum GFAP as a biomarker for disease severity in multiple sclerosis

Author Correction: Serum GFAP as a biomarker for disease severity in multiple sclerosis

GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA)

Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker?

Mapping of Disease Severity in Patients with Systemic Sclerosis

Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity

Refining the concept of GFAP toxicity in Alexander disease

Predicting disease severity in multiple sclerosis using multimodal data and machine learning

Genetics of disease severity in multiple sclerosis, Alzheimer’s disease, and Huntington’s disease: rejuvenating genome-wide association studies

Disease severity classification using passively collected smartphone-based keystroke dynamics within multiple sclerosis

Gut microbial factors predict disease severity in a mouse model of multiple sclerosis

Correlation of trans fatty acids with the severity of coronary artery disease lesions

Serum GFAP as a biomarker for disease severity in multiple sclerosis

Author Correction: Serum GFAP as a biomarker for disease severity in multiple sclerosis

GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA)

Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker?

Mapping of Disease Severity in Patients with Systemic Sclerosis

Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity

Refining the concept of GFAP toxicity in Alexander disease

Predicting disease severity in multiple sclerosis using multimodal data and machine learning

Genetics of disease severity in multiple sclerosis, Alzheimer’s disease, and Huntington’s disease: rejuvenating genome-wide association studies

Disease severity classification using passively collected smartphone-based keystroke dynamics within multiple sclerosis

Gut microbial factors predict disease severity in a mouse model of multiple sclerosis

Correlation of trans fatty acids with the severity of coronary artery disease lesions

Related objects

Reset password